Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.46 |
| ▸ | MDM4 | O15151 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517361 | 0.77 | MDM4 (0.42) | MDM2MDM4TP53CASP3 | |
| SCHEMBL30262997 | 0.77 | MDM4 (0.42) | MDM2MDM4TP53CASP3 | |
| SCHEMBL25816905 | 0.77 | MDM4 (0.42) | MDM2MDM4TP53CASP3 | |
| SCHEMBL30517343 | 0.75 | FABP5 (0.39) | MDM4TP53 | |
| SCHEMBL25816888 | 0.75 | FABP5 (0.39) | MDM4TP53 | |
| SCHEMBL30133561 | 0.75 | MDM2 (0.50) | MDM2MDM4TP53BACE1CASP3 | |
| SCHEMBL25355242 | 0.75 | BACE1 (0.53) | MDM2MDM4TP53BACE1IDO1 | |
| SCHEMBL5434114 | 0.75 | BACE1 (0.53) | MDM2MDM4TP53BACE1IDO1 | |
| SCHEMBL31627392 | 0.75 | BACE1 (0.53) | MDM2MDM4TP53BACE1IDO1 | |
| SCHEMBL25356332 | 0.75 | BACE1 (0.53) | MDM2MDM4TP53BACE1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039714-A1 | Probes, Systems, and Methods for Drug Discovery | VTVX HOLDINGS I LLC | 2011-02-17 | — | — | US | disclosed |
| EP-1383799-A1 | PROBES, SYSTEMS AND METHODS FOR DRUG DISCOVERY | TransTech Pharma Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003084997-A1 | PROBES, SYSTEMS AND METHODS FOR DRUG DISCOVERY | TRANSTECH PHARMA, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030125315-A1 | Probes, systems, and methods for drug discovery | TRANSTECH PHARMA, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125315-A1 | Probes, systems, and methods for drug discovery | ABCG2, EZR, PAICS | MDM2 269/4885MDM4 252/4885TP53 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.